 Galera Therapeutics NASDAQ:GRTX was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The brokerage currently has a 14.00 target price on the stock. Zacks Investment Researchs price objective would indicate a potential downside of 2.85 from the ... 